This company has been marked as potentially delisted and may not be actively trading. aTyr Pharma (LIFE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock LIFE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYROctober 12 at 1:50 PM | markets.businessinsider.comaTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial FailureOctober 10, 2025 | quiverquant.comQMidnight Sun Mining increases 'bought deal' LIFE offering to C$17.5MOctober 3, 2025 | proactiveinvestors.comMidnight Sun Announces Upsize to Previously Announced “Bought Deal†LIFE Offering and Private Placement of Units to C$17.5 MillionOctober 3, 2025 | globenewswire.comMidnight Sun Mining to raise C$10M in 'bought deal' LIFE offeringOctober 2, 2025 | proactiveinvestors.comEthos Technologies Targets IPO Amid Positive Insurance OfferingsSeptember 30, 2025 | seekingalpha.comDomestic Metals Announces Upsize of LIFE Offering of UnitsSeptember 30, 2025 | globenewswire.comaTyr Pharma Reports Clinical Benefits of Efzofitimod in Phase 3 Study for Pulmonary SarcoidosisSeptember 30, 2025 | quiverquant.comQTABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIASeptember 29, 2025 | prnewswire.comEthos Files Registration Statement for Proposed Initial Public OfferingSeptember 26, 2025 | globenewswire.comaTyr Pharma Reports Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis, Highlighting Clinical Improvements Despite Primary Endpoint Not MetSeptember 15, 2025 | quiverquant.comQEloro Resources Announces Further Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$11.0 MillionAugust 27, 2025 | globenewswire.com2 Small-Cap Biotech Stocks Well Positioned for a BreakoutAugust 27, 2025 | fool.comaTyr Pharma (ATYR) Receives a Buy from Piper SandlerAugust 25, 2025 | theglobeandmail.comPulmonary Sarcoidosis Treatment Landscape Evolves with Corticosteroid Alternatives and Targeted Therapies | DelveInsightAugust 21, 2025 | theglobeandmail.comATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod ExpectationsAugust 19, 2025 | insidermonkey.comTerra Balcanica Closes Fully Subscribed LIFE OfferingAugust 13, 2025 | globenewswire.com1 Small-Cap Biotech Stock Poised for a BreakoutAugust 6, 2025 | msn.comMartin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here?July 31, 2025 | msn.comInsurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of DirectorsJuly 30, 2025 | globenewswire.comQ2 Metals Announces $20 Million LIFE Private Placement of Flow-Through SharesJuly 23, 2025 | globenewswire.comFirst Nordic Metals Announces C$10 Million “Best Efforts†LIFE Offering of UnitsJuly 9, 2025 | globenewswire.comaTyr: Promising Data, But Cash May Be An IssueJune 10, 2025 | seekingalpha.comVortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private PlacementMay 22, 2025 | globenewswire.comaTyr Pharma, Inc. (ATYR): Analysts See 485% Upside PotentialMay 21, 2025 | insidermonkey.comVortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private PlacementApril 24, 2025 | globenewswire.comIs aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?March 27, 2025 | insidermonkey.comaTyr Pharma (ATYR) Receives a Buy from Wells FargoMarch 18, 2025 | markets.businessinsider.comaTyr Pharma director buys $15K in common stockMarch 18, 2025 | markets.businessinsider.comaTyr Pharma’s Earnings Call Highlights Progress and ChallengesMarch 14, 2025 | tipranks.comaTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...March 14, 2025 | gurufocus.comQ4 2024 aTyr Pharma Inc Earnings Call TranscriptMarch 13, 2025 | gurufocus.comaTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Estimates, Revenue at $0. ...March 13, 2025 | gurufocus.comAtyr Pharma Shares Rise After Lung Disease Treatment Passes Safety ReviewMarch 7, 2025 | marketwatch.comaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary SarcoidosisMarch 7, 2025 | finanznachrichten.deaTyr Pharma announces DSMB recommendation for EFZO-FIT study to continueMarch 7, 2025 | markets.businessinsider.comTREATMENT.COM AI INC. ANNOUNCES LISTED ISSUER FINANCING EXEMPTION (LIFE) BOUGHT DEAL PRIVATE PLACEMENTFebruary 27, 2025 | globenewswire.comAmerican Tungsten Announces Closing of Upsized and Oversubscribed Non-Brokered LIFE Offering of SharesFebruary 26, 2025 | globenewswire.comLeerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFebruary 19, 2025 | msn.comaTyr Pharma initiated with an Outperform at LeerinkFebruary 18, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: aTyr Pharma (ATYR), Crispr Therapeutics AG (CRSP) and American Well (AMWL)February 13, 2025 | markets.businessinsider.comSeveral Insiders Invested In aTyr Pharma Flagging Positive NewsJanuary 10, 2025 | finance.yahoo.comaTyr Pharma: Interesting Drug, Difficult Target MarketJanuary 8, 2025 | seekingalpha.comaTyr Pharma initiated with an Overweight at Cantor FitzgeraldJanuary 7, 2025 | markets.businessinsider.comCantor Fitzgerald Initiates Coverage of aTyr Pharma (ATYR) with Overweight RecommendationJanuary 7, 2025 | msn.comaTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comaTyr Pharma to present preclinical research on ATYR0101 at symposia on FirbosisDecember 9, 2024 | markets.businessinsider.comaTyr Pharma stock rated Buy; Lucid notes Efzofitimod's potential in lung diseasesNovember 21, 2024 | uk.investing.comaTyr Pharma initiated with a Buy at Lucid CapitalNovember 20, 2024 | markets.businessinsider.comCerro de Pasco Resources Announces Amendment to LIFE Offering DocumentNovember 19, 2024 | globenewswire.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIFE Media Mentions By Week LIFE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIFE News Sentiment▼0.000.75▲Average Medical News Sentiment LIFE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIFE Articles This Week▼21▲LIFE Articles Average Week Get the Latest News and Ratings for LIFE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for aTyr Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Pacific Biosciences of California News Today Harvard Bioscience News Today Thermo Fisher Scientific News Today Agilent Technologies News Today Mettler-Toledo International News Today Waters News Today Illumina News Today Bio-Techne News Today Charles River Laboratories International News Today Bio-Rad Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIFE) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
